Vor Biopharma Inc. (VOR)
NASDAQ: VOR · Real-Time Price · USD
1.970
-0.040 (-1.99%)
At close: Aug 29, 2025, 4:00 PM
2.000
+0.030 (1.52%)
After-hours: Aug 29, 2025, 7:59 PM EDT
Vor Biopharma Employees
Vor Biopharma had 159 employees as of December 31, 2024. The number of employees decreased by 9 or -5.36% compared to the previous year.
Employees
159
Change (1Y)
-9
Growth (1Y)
-5.36%
Revenue / Employee
n/a
Profits / Employee
-$10,468,088
Market Cap
249.57M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 159 | -9 | -5.36% |
| Dec 31, 2023 | 168 | 35 | 26.32% |
| Dec 31, 2022 | 133 | -2 | -1.48% |
| Dec 31, 2021 | 135 | 47 | 53.41% |
| Dec 31, 2020 | 88 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VOR News
- 5 days ago - Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy - GlobeNewsWire
- 6 days ago - Vor Bio to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 14 days ago - Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 19 days ago - Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate - Benzinga
- 19 days ago - Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor - GlobeNewsWire
- 4 weeks ago - Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer - GlobeNewsWire
- 6 weeks ago - Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors - GlobeNewsWire
- 6 weeks ago - Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire